Skip to main content
Kanwal Raghav, MD, Oncology, Houston, TX

Kanwal Pratap Singh Raghav MD


Physician

Join to View Full Profile
  • 1515 Holcombe BlvdHouston, TX 77030

  • Phone+1 713-792-6161

Are you Dr. Raghav?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Kanwal Raghav, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona.

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
  • Albert Einstein Healthcare Network
    Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2006 - 2009
  • University of Arkansas For Medical Sciences College of Medicine
    University of Arkansas For Medical Sciences College of MedicineClass of 2005
  • Delhi University College of Medical Sciences
    Delhi University College of Medical SciencesClass of 2004

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • AZ State Medical License
    AZ State Medical License 2024 - 2026
  • OK State Medical License
    OK State Medical License 2020 - 2026
  • OK State Medical License
    OK State Medical License 2020 - 2026
  • TN State Medical License
    TN State Medical License 2024 - 2026
  • AL State Medical License
    AL State Medical License 2024 - 2025
  • GA State Medical License
    GA State Medical License 2024 - 2025
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology
  • Join now to see all

Publications & Presentations

PubMed

Press Mentions

  • New Anti-HER2 Therapy Shows Promise as a Less Toxic Option for HER2+ Colorectal Cancer
    New Anti-HER2 Therapy Shows Promise as a Less Toxic Option for HER2+ Colorectal CancerJanuary 29th, 2025
  • MD Anderson Research Highlights for August 21, 2024
    MD Anderson Research Highlights for August 21, 2024August 21st, 2024
  • Confirmed Antitumor Activity with T-dXd for HER2-Positive Metastatic CRC
    Confirmed Antitumor Activity with T-dXd for HER2-Positive Metastatic CRCAugust 16th, 2024
  • Join now to see all